Ashkenazi A - Search Results

1

Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity.

Johnsen AC, Haux J, Steinkjer B, Nonstad U, Egeberg K, Sundan A, Ashkenazi A, Espevik T. Johnsen AC, et al. Among authors: ashkenazi a. Cytokine. 1999 Sep;11(9):664-72. doi: 10.1006/cyto.1999.0489. Cytokine. 1999. PMID: 10479402

2

Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages.

Halaas O, Vik R, Ashkenazi A, Espevik T. Halaas O, et al. Among authors: ashkenazi a. Scand J Immunol. 2000 Mar;51(3):244-50. doi: 10.1046/j.1365-3083.2000.00671.x. Scand J Immunol. 2000. PMID: 10736093 Free article.

3

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.

Almasan A, Ashkenazi A. Almasan A, et al. Among authors: ashkenazi a. Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48. doi: 10.1016/s1359-6101(03)00029-7. Cytokine Growth Factor Rev. 2003. PMID: 12787570 Review.

4

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Pitti RM, et al. Among authors: ashkenazi a. J Biol Chem. 1996 May 31;271(22):12687-90. doi: 10.1074/jbc.271.22.12687. J Biol Chem. 1996. PMID: 8663110 Free article.

5

Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA.

Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Marsters SA, et al. Among authors: ashkenazi a. Curr Biol. 1996 Jun 1;6(6):750-2. doi: 10.1016/s0960-9822(09)00456-4. Curr Biol. 1996. PMID: 8793301 Free article.

6

Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1.

Zhou Q, Fukushima P, DeGraff W, Mitchell JB, Stetler Stevenson M, Ashkenazi A, Steeg PS. Zhou Q, et al. Among authors: ashkenazi a. Cancer Res. 2000 May 15;60(10):2611-5. Cancer Res. 2000. PMID: 10825131

7

Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.

Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A. Pitti RM, et al. Among authors: ashkenazi a. Nature. 1998 Dec 17;396(6712):699-703. doi: 10.1038/25387. Nature. 1998. PMID: 9872321

8

Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D.

Mori S, Murakami-Mori K, Nakamura S, Ashkenazi A, Bonavida B. Mori S, et al. Among authors: ashkenazi a. J Immunol. 1999 May 1;162(9):5616-23. J Immunol. 1999. PMID: 10228045

9

Targeting the extrinsic apoptosis pathway in cancer.

Ashkenazi A. Ashkenazi A. Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):325-31. doi: 10.1016/j.cytogfr.2008.04.001. Epub 2008 May 20. Cytokine Growth Factor Rev. 2008. PMID: 18495520 Review.

10

Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B.

Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, Bauer KD, Ashkenazi A. Marsters SA, et al. Among authors: ashkenazi a. Curr Biol. 1996 Dec 1;6(12):1669-76. doi: 10.1016/s0960-9822(02)70791-4. Curr Biol. 1996. PMID: 8994832 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

551 results

Search Page